Breast Cancer Receptor Discordance in 436 Paired Primary-Metastatic Lesions, 2013-2023

Sijie Chen's retrospective study analyzes 436 paired lesion samples from primary and metastatic breast cancer treated between 2013 and 2023. The dataset likely contains receptor status (ER, PR, HER2), molecular subtypes, clinicopathological correlations, and survival outcomes. It was uploaded to figshare on April 20, 2026, under a CC-BY-4.0 license.

Use Cases

• Modeling the probability of receptor status change based on metastasis site and prior treatment.
• Analyzing the correlation between biomarker discordance and overall survival outcomes.
• Identifying clinicopathological factors associated with specific transitions in hormone receptor or HER2 expression.

Strengths

• Provides specific discordance rates: 25.1% for ER, 33.3% for PR, 32.8% for HER2, and 33.8% for molecular subtypes.
• Includes survival analysis with median OS differences (e.g., 95 vs. 70 months for HR loss) and statistical significance (P values).
• Covers a decade of clinical data (2013-2023) from a single-center study of 363 cases.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (12.9 KB), suggesting limited raw data or a summary document.

Provenance

Source

Sijie Chen

Collection Method

Retrospective analysis of paired lesion samples from a single center.

Time Range

2013 to 2023

Freshness

Last updated 2026-04-20 04:13:13; freshness should be verified.

Geography

null